MedTrace Logo

Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases

NCT01959061 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2017-03-13

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

Raltitrexed

4mg, every 4 weeks,transhepatic arterial infusion

DRUG

Oxaliplatin

100\~150mg, every 4 weeks, transhepatic arterial infusion

DRUG

lipiodol

5-20ml, every 4 weeks, hepatic artery embolization

Sponsors & Collaborators

  • Nanjing Chia-tai Tianqing Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Jianhua Wang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959061 on ClinicalTrials.gov